Stéphane Barete

2 weeks ago | nature.com | Remy Duléry |Vincent Guiraud |Sylvain Choquet |Catherine Thieblemont |Emmanuel Bachy |Stéphane Barete | +3 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03458-w, published online 8 January 2025. In the version of the article initially published, in the sixth paragraph, the text “… at chromosome 11:63,540,796 (hg19)” should have read “… at chromosome 11:63,540,796 (hg38)” and has now been corrected in the HTML and PDF versions of the article. About this articleDulery, R., Guiraud, V., Choquet, S. et al.

Jan 8, 2025 | nature.com | Remy Duléry |Vincent Guiraud |Sylvain Choquet |Catherine Thieblemont |Emmanuel Bachy |Stéphane Barete | +3 more

AbstractThe risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018.